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Type 2 inflammation in eosinophilic chronic obstructive 
pulmonary disease
To the Editor,
Type 2 (T2) inflammation in asthma encompasses the presence of 
eosinophilic inflammation and/or selected cytokines including inter-
leukin (IL)-13. Some chronic obstructive pulmonary disease (COPD) 
patients have increased airway eosinophil numbers,1 which is associ-
ated with greater effects of inhaled corticosteroids (ICS).2 Studies of T2 
inflammation in COPD have used hypothesis free, open platform ap-
proaches.3,4 We used these results, plus data from T2 asthma studies,5 
to test a restricted panel of biomarkers (chloride channel accessory 1 
[CLCA1], periostin [POSTN], serpin family B member 2 [SERPINB2], C-C 
motif chemokine ligand 26 [CCL26], IL-13 and cystatin SN [CST1]) to 
further investigate the nature of T2 inflammation in eosinophilic COPD.
We used two cohorts: bronchial brushings and sputum were ob-
tained from 17 eosinophilhigh and 20 eosinophillow COPD patients 
(bronchoscopy cohort previously reported1: eosinophilhigh defined 
as blood eosinophils > 250 eosinophils µL−1 and eosinophillow de-
fined as blood eosinophils < 150 eosinophils µL−1) and sputum only 
was obtained from 15 eosinophilhigh and 18 eosinophillow COPD 
patients (validation cohort: eosinophilhigh defined as > 150 eosin-
ophils µL−1 blood and > 3% sputum eosinophils and eosinophillow 
defined as < 150 eosinophils µL−1 blood and < 3% sputum eosin-
ophils). Full details of inclusion criteria and clinical characteristics 
are in the Appendix S1 and Table 1. Both cohorts were generally 
well matched. RNA sequencing examined gene expression in the 
bronchoscopy cohort, while RT-qPCR was used in the validation 
cohort. Full details of methods and analysis are in the Appendix S1.
In the bronchoscopy cohort, bronchial epithelial gene expression 
of CLCA1, CCL26, IL-13 and CST1 was significantly higher (P < .05) 
in eosinophilhigh versus eosinophillow COPD patients (Figure 1) with 
fold change differences of 1.9, 2.2, 2.9 and 2.5, respectively. POSTN 
and SERPINB2 expression trended higher in eosinophilhigh versus eo-
sinophillow COPD patients but did not achieve statistical significance 
(P = .06 and P = .07, respectively; Figure S1).
In the bronchoscopy and validation cohorts, sputum gene ex-
pression of CLCA1, CCL26, IL-13 and CST1 was significantly higher 
(P < .05) in eosinophilhigh versus eosinophillow COPD patients 
(Figure 1); fold change differences were 3.1, 2.0, 1.8 and 3.5 for 
the bronchoscopy cohort and 28.2, 9.4, 6.0 and 79.3 for the vali-
dation cohort, respectively. Expression of POSTN and SERPINB2 
was not different between groups (Figure S1). ICS use and smoking 
status did not influence gene expression (data not shown). There 
was a significant positive correlation between a four-gene mean 
and sputum eosinophil counts in both cohorts (rho 0.6 to 0.7 and 
P < .001; Figure S1), but not other cell types (data not shown).
We report that eosinophilic COPD is associated with a profile of 
T2 inflammation in both bronchial epithelium and sputum samples; 
this was consistently observed in sputum samples from two inde-
pendent cohorts. We tested six genes associated with T2 inflamma-
tion in asthma and observed increased expression of four of these 
genes (CLCA1, CCL26, IL-13 and CST1) in eosinophilhigh compared to 
eosinophillow COPD patients. The strengths of this study include a 
validation cohort, and different lung samples (bronchial epithelium 
and sputum). The positive signals were > 1.8-fold higher (gene ex-
pression) in the eosinophilhigh group. Different techniques (RNA se-
quencing and RT-qPCR) were used to analyse sputum samples, but 
the conclusions and relative fold changes showed the same pattern, 
adding confidence to our observations. The association between eo-
sinophils and IL-13 expression levels suggests pathways linking eo-
sinophilic inflammation to airway remodelling and mucus secretion,6 
discussed further in the Appendix S1.
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These results indicate a wider profile of T2 inflammation in eo-
sinophilic COPD that extends to mechanisms including IL-13 driven 
pathways. While T2 inflammation is well recognized in asthma, we 
now provide further evidence of T2 inflammation in a subset of 
COPD patients. The components of T2 inflammation described here 
may represent therapeutic targets.
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TA B L E  1   Clinical Characteristics of the Bronchoscopy and Validation cohorts
Characteristic
Bronchoscopy Cohort Validation Cohort
Eosinophillow Eosinophilhigh P value Eosinophillow Eosinophilhigh P value
Number 17 20 N/A 18 15 N/A
Age (y) 62 ± 6 62 ± 4 .7 64 ± 8 67 ± 9 .3
Gender: Male (%) 65 70 .7 44 73 .1
BMI (kg/m2) 27 ± 5 25 ± 4 .2 25 ± 5 28 ± 4 .06
Current smokers (%) 42 60 .2 61 20 .01
Pack-years history 43 ± 15 38 ± 14 .3 48 ± 19 45 ± 25 .7
ICS use (%) 82 55 .08 39 93 .02
ICS dose 0 (0-2000) 800 (0-2000) .009 1000 (0-2000) 600 (0-2000) .35
Post-bronchodilator FEV1 (L) 1.9 ± 0.4 1.9 ± 0.4 .9 1.7 ± 0.6 1.8 ± 0.5 .6
Postbronchodilator FEV1 (% predicted) 64 ± 12 66 ± 11 .6 67 ± 17 66 ± 16 .8
Postbronchodilator FVC (L) 3.8 ± 1.3 3.6 ± 0.9 .5 3.2 ± 1 3.3 ± 0.7 .7
Postbronchodilator FEV1/FVC ratio 50 ± 10 53 ± 7 .3 53 ± 12 55 ± 11 .7
Reversibility (mL) 207 ± 189 217 ± 154 .9 166 ± 142 145 ± 147 .7
FeNO50 (ppm) 16 ± 8.4 23 ± 15 .2 9.2 ± 5.2 14.9 ± 8.1 .02
Atopy (% positive) 0 0 N/A 6 13 .4
Total SGRQ 42 ± 17 37 ± 21 .4 56 ± 16 55 ± 16 .9
mMRC 1.8 ± 1.0 1.3 ± 1.2 .2 3.6 ± 0.7 3.7 ± 0.6 .6
CAT 19 ± 9 17 ± 8 .4 22 ± 7 22 ± 6 1
Exacerbation rate, 12 mo prior 0.8 (0-3) 0.7 (0-3) .6 0.8 (0-4) 1.6 (0-4) .04
Blood Eosinophils 10 ± 3 432 ± 144 <.0001 9 ± 3 350 ± 240 <.0001
Sputum Cell Counts
Total (×106/g) 5.6 (0.1-26.3) 5.9 (0.5-32.4) .9 1.9 (0.2-11.4) 2.4 (0.8-12.6) .2
Neutrophil (×106/g) 3.2 (0.1-20.8) 3.6 (0.2-29.6) .9 3.9 (0.5-24.4) 5.4 (0.4-16.6) .8
Macrophage (×106/g) 1.3 (0.01-4.6) 1.2 (0.2-7.7) .6 1.4 (0.3-3.5) 1.3 (0.4-4.5) .5
Eosinophil (×106/g) 0.02 (0.0-0.2) 0.3 (0.01-4.2) <.001 0.04 (0.00 
- 0.4)
0.3 (0.1-1.3) <.001
Lymphocyte (×106/g) 0.02 (0.0-0.1) 0.02 (0.0-0.2) .4 0.04 (0.0-0.6) 0.01 (0.0-0.2) .4
Epithelial (×106/g) 0.04 (0.0-0.7) 0.03 (0.0-1.0) .7 0.1 (0.02-0.6) 0.2 (0.04-1.6) .07
Eosinophils (%) 0.5 (0-2.5) 4.5 (0.3-70) <.0001 0.5 (0-2) 6.5 (2.8-16.5) <.0001
Neutrophils (%) 81 (17-91) 63 (15-91) .06 67 ± 20 65 ± 18 .8
Macrophages (%) 17 (5-82) 23 (4-63) .6 30 ± 19 23 ± 15 .3
Lymphocytes (%) 0.5 (0-2.3) 0.3 (0-2.5) .3 0.3 (0-2.8) 0.3 (0-3.5) .8
Epithelial (%) 1 (0-8) 1 (0-8) .85 2 (0.3-10) 3 (0.3-17) .08
Note: Data presented as %, mean ± standard deviation, or median (range).
Abbreviations: BMI, body mass index; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FeNO50, 
fractional exhaled nitric oxide at 50 mL−1 s flow rate; PPM, parts per million; SGRQ, St George's Respiratory Questionnaire; mMRC, modified Medical 
Research Council; CAT, COPD Assessment Test.
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F I G U R E  1   T2 gene expression in bronchial brushings and sputum from the bronchoscopy and validation cohorts. RNA sequencing 
was used to examine the expression of CLCA1 (A, E, and I), CCL26 (B, F and J), IL-13 (C, G and K), CST1 (D, H and L), in RNA isolated from 
bronchial brushings (A-D) and sputum cells (E-H) from the bronchoscopy cohort and sputum cells from the validation cohort (I-L). Data 
presented as individual data points with mean (A-H) or median (I-L) where *, ** and *** = significant difference (P < .05, P < .01 and P < .001, 
respectively). For A-H, gene expression was normalized to the transcript length for each gene. For I-L, gene expression was normalized to 
GAPDH
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Inhibition of CpG methylation improves the barrier integrity of 
bronchial epithelial cells in asthma
To the Editor,
Asthma is a complex and heterogeneous chronic airway inflamma-
tory disease with the involvement of environmental factors through 
epigenetic mechanisms.1 Accordingly, repeated injury, repair, and re-
generation of the airway epithelium following exposure to environ-
mental factors and inflammation results in histological changes and 
functional abnormalities in the airway mucosal epithelium, which are 
associated with the pathophysiology of asthma.2 Epigenetics is de-
fined by heritable changes in gene expression without changes in the 
DNA sequence.3 Regulation of gene expression is mediated by dif-
ferent mechanisms such as DNA methylation, histone modifications, 
and RNA-associated silencing by small non-coding RNAs. CpG sites 
are dinucleotides consisting of guanine and cytosine concentrated in 
clusters referred to CpG islands found at important regulatory sites, 
such as promoter and enhancer regions.4 Their de novo methylation 
occurs in response to various cellular stressors and signals by DNA 
methyltransferases (DNMT3a and 3b), which add a methyl group to 
position 5 of cytosine residues at the CpG site. During DNA replica-
tion, both of the separated strands of DNA carry one methylated 
cytosine to be used as a template for duplication. Daughter DNA 
duplex strands will thus be hemi-methylated, which is recognized by 
a different DNA methyltransferase isoform (DNMT1). Because DNA 
methylation is a reversible process, the DNMTs are considered as 
a therapeutic target. Several DNMT inhibitors have been identified 
recently, among the non-nucleoside inhibitors, 4-aminoquinoline-
based inhibitors, such as SGI-1027 showed potent inhibitory activ-
ity. SGI-1027 occupies the binding site of DNMTs resulting in the 
prevention of access of target DNA to the substrate binding pocket.5
We have demonstrated in previous studies from our laboratory 
that human primary bronchial epithelial cells (HBEC) isolated from 
patients with asthma showed lower barrier integrity compared to 
controls.6 Seeing that important role of DNA methylation in lung 
cells and asthma pathogenesis by other groups,7 we investigate the 
level of global methylation in HBEC of control and asthma samples 
for the long interspersed nuclear element-1 (LINE-1) methylation 
levels (Figure 1A). HBEC from asthma patients showed a tendency 
for higher global methylation levels, together with higher expres-
sion of 5-methylcytosine (5-mc) in immunofluorescence staining 
(Figure 1B). Next, we performed methylation profiling (Illumina 
Infinium EPIC array) to investigate genes methylated in ALI cultures 
of HBEC. Interestingly, in a highly methylated group of top 100 genes, 
we found many genes associated with cell growth, ion transport, and 
cytoskeletal remodeling (Figure S1). Several pro-inflammatory cyto-
kines had lower methylation levels, whereas regulatory cytokines, 
such as IL10RA and TGFBR2, were methylated (Figure S2). In genes 
involved in the epigenetic process, we found members of histone de-
methyltransferases, histone deacetylases in both groups, but inter-
estingly ten-eleven translocation enzyme (TET1), which can reverse 
CpG methylation was methylated. On the other side, genes belong 
to protein arginine methyltransferases (PRMT) were not methylated. 
Many genes specifically involved in the regulation of bronchial bar-
rier integrity showed higher methylation (eg, TJ family members: 
AMOTL1, CLDN11, CLDN18, MAGI1, TJP2, JAM3, actin protein: ACTB, 
a component of the cytoskeleton: TUBA1C, ROCK2, LLGL1). We kept 
our attention on the methylated epigenetic and tight junction (TJ) 
genes and further focused on TJs, especially zonula occludens and 
claudins which showed higher methylation in contrast to occludin, 
which was not methylated (Figure 1C). As higher methylation levels 
were observed in HBEC of asthmatic origin, we inhibited the DNA 
methyltransferase enzyme with a specific inhibitor, SGI-1027, to 
Abbreviations: ALI, air-liquid interface; BEGM, bronchial epithelial growth medium; DNMT, DNA methyltransferase; FITC, fluorescein isothiocyanate; HBEC, human bronchial epithelial 
cells; LINE-1, long interspersed nuclear element-1; 5-mc, 5-methylcytosine; TER, transepithelial electric resistance; ZO, zonula occludens.
